DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20171117

Imiquimod triggering varicella zoster reactivation in an immunocompetent patient

Thomas Jonathan Stewart, Andrea Tomizawa, Robert Rosen

Abstract


Imiquimod is widely used for the treatment of superficial basal cell carcinoma as well as several other dermatologic conditions. While its local immunostimulatory action is well proven, its potential for systemic immunomodulation has been less well described. We report the first case (to our knowledge) of varicella zoster reactivation caused by Imiquimod in an immunocompetent patient. 


Keywords


Drug reaction, Imiqumod, Varicella zoster reactivation

Full Text:

PDF

References


Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan S. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348:2911.

Rosenblatt A, de Campos Guidi HG. Local and systemic adverse effects of imiquimod therapy for external anogenital warts in men: report of three cases. Int J STD AIDS. 2012;23(12):909-10.

Smith WA, Siegel D, Lyon VB, Holland KE. Psoriasiform eruption and oral ulcerations as adverse effects of topical %% imiquimod treatment in children: a report of four cases. Pediatr Dermatol. 2013;30(6):e157-60.

Hanger C, Dalrymple J, Hepburn. Systemic side effects from topical imiquimod. NZ Med J. 2005;118:1223.

Kumar B, Narang T. Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation. Sex Transm Infect. 2011;87:432.

Heikkinen AK, Susitaival P. Severe systemic reaction to topical imiquimod. Acta Derm Venereol. 2011;91(5):594-5.

Lu H. TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects. Front Immunol. 2006;5:83.

Peng JC, Abu Bakar, S, Richardson MM, Jonsson JJ, Frazer IH, Nielsen LK, et al. IL10 and IL12B polymorphisms each influence IL12p70 secretion by dendritic cells in response to LPS. Immunol Cell Biol. 2006;84:227-32.

Vaknin I, Blinder L, Wang L, Gazit R, Shapira E, Genina O, et al. A common pathway mediated through Toll-like receptors leads to T- and natural killer cell immunosuppression. Blood. 2008;111:1437-47.

Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 2006;107:628-36.